Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Stephanie L. Borgland, Drew M. Neyens
Journal of Psychiatry and Neuroscience June 1, 2022 DOI: 10.1503/jpn.220090 via OpenAlex
Summary
AI-generated from the abstractPrivate clinics and registered clinical trials using serotonergic psychedelics for psychiatric conditions such as substance use disorder and major depressive disorder have grown substantially. Classical psychedelics include lysergic acid diethylamide.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression LSD Serotonin |
| Keywords | Psychiatry Hallucinogen Medicine |
| Citations | 14 |
| Key finding | There has been substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for psychiatric illnesses including substance use disorder and major depressive disorder. |
Abstract
There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid